Protocol Ledger

NCT03401788 · Phase II · ACTIVE NOT RECRUITING

A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

Interventional Phase II clinical trial protocol NCT03401788 sponsored by Merck & Co. in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-02 Enrollment: 50 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03401788
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)50 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03401788
Protocol FieldVerified Registry Value
NCT IdentifierNCT03401788
Consolidated Lead SponsorMerck & Co.
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment50 participants (ESTIMATED)
Registered Start Date2018-05-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI